다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Immunotargets and therapy, v.2, 2013년, pp.11 - 19
Krishnadas, Deepa Kolaseri (Department of Pediatrics, Division of Hematology) , Bai, Fanqi (Department of Pediatrics, Division of Hematology) , Lucas, Kenneth G (Department of Pediatrics, Division of Hematology)
AI-Helper
The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in ...
1 Yee C Thompson JA Byrd D Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and anti-tumor effect of transferred T cells Proc Natl Acad Sci U S A 2002 99 25 16168 16173 12427970
2 Dudley ME Wunderlich JR Robbins PF Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 5594 850 854 12242449
3 Yu JS Liu G Ying H Yong WH Black KL Wheeler CJ Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Res 2004 64 14 4973 4979 15256471
4 Kono K Takahashi A Sugai H Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer Clin Cancer Res 2002 8 11 3394 3400 12429626
5 Comito MA Sun Q Lucas KG Immunotherapy for Epstein-Barr virus-associated tumors Leuk Lymphoma 2004 45 10 1981 1987 15370241
6 Riddell SR Greenberg PD Principles for adoptive T cell therapy of human viral diseases Annu Rev Immunol 1995 13 545 586 7612234
7 Walter EA Greenberg PD Gilbert MJ Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N Engl J Med 1995 333 16 1038 1044 7675046
8 Curran KJ Pegram HJ Brentjens RJ Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions J Gene Med 2012 14 6 405 415 22262649
9 Morgan RA Dudley ME Wunderlich JR Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129 16946036
10 Kerkar SP Sanchez-Perez L Yang S Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies J Immunother 2011 34 4 343 352 21499127
11 Choi BD Cai M Bigner DD Mehta AI Kuan CT Sampson JH Bispecific antibodies engage T cells for antitumor immunotherapy Expert Opin Biol Ther 2011 11 7 843 853 21449821
12 Baitsch L Baumgaertner P Devêvre E Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients J Clin Invest 2011 121 6 2350 2360 21555851
13 Norde WJ Hobo W van der Voort R Dolstra H Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention Blood 2012 120 4 728 736 22563087
14 Gao J Bernatchez C Sharma P Radvanyi LG Hwu P Advances in the development of cancer immunotherapies Trends Immunol 2013 34 2 90 98 23031830
15 Zhou Q Munger ME Highfill SL Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia Blood 2010 116 14 2484 2493 20570856
16 Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 26 2443 2454 22658127
17 Brahmer JR Tykodi SS Chow LQ Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 2012 366 26 2455 2465 22658128
18 Peggs KS Quezada SA Chambers CA Korman AJ Allison JP Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies J Exp Med 2009 206 8 1717 1725 19581407
19 Weber J Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events Oncologist 2007 12 7 864 872 17673617
20 Hodi FS O’Day SJ McDermott DF Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010 363 8 711 723 20525992
21 Margolin K Ernstoff MS Hamid O Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 2012 13 5 459 465 22456429
22 Weber JS Amin A Minor D Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial Melanoma Res 2011 21 6 530 534 22051508
23 Di Giacomo AM Ascierto PA Pilla L Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Lancet Oncol 2012 13 9 879 886 22894884
24 Robert C Thomas L Bondarenko I Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 2011 364 26 2517 2526 21639810
25 Bolhassani A Safaiyan S Rafati S Improvement of different vaccine delivery systems for cancer therapy Mol Cancer 2011 10 3 21211062
26 Bendandi M Gocke CD Kobrin CB Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Nat Med 1999 5 10 1171 1177 10502821
27 Gnjatic S Sawhney NB Bhardwaj N Toll-like receptor agonists: are they good adjuvants? Cancer J 2010 16 4 382 391 20693851
28 Palucka K Banchereau J Cancer immunotherapy via dendritic cells Nat Rev Cancer 2012 12 4 265 277 22437871
29 Simpson AJ Caballero OL Jungbluth A Chen YT Old LJ Cancer/testis antigens, gametogenesis and cancer Nat Rev Cancer 2005 5 8 615 625 16034368
30 Chen YT Ross DS Chiu R Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers PLoS One 2011 6 3 e17876 21437249
31 Caballero OL Chen YT Cancer/testis (CT) antigens: potential targets for immunotherapy Cancer Sci 2009 100 11 2014 2021 19719775
32 Restifo NP Dudley ME Rosenberg SA Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 2012 12 4 269 281 22437939
33 Scanlan MJ Simpson AJ Old LJ The cancer/testis genes: review, standardization, and commentary Cancer Immun 2004 4 1 14738373
34 Nicholaou T Ebert L Davis ID Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1 Immunol Cell Biol 2006 84 3 303 317 16681828
35 Zhang S Zhou X Yu H Yu Y Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines BMC Cancer 2010 10 163 20423514
36 Wang XF Cohen WM Castelli FA Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family Cancer Immunol Immunother 2007 56 6 807 818 16988823
37 Luiten R Demotte N Tine J van der Bruggen P A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules Tissue Antigens 2000 56 1 77 81 10958359
38 Luiten R van der Bruggen P A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes Tissue Antigens 2000 55 2 149 152 10746786
39 Pastorcic-Grgic M Sarcevic B Dosen D Juretic A Spagnoli GC Grgic M Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer Head Neck 2010 32 9 1178 1184 20029985
40 Yoshida N Abe H Ohkuri T Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance Int J Oncol 2006 28 5 1089 1098 16596224
41 Jungbluth AA Antonescu CR Busam KJ Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7 Int J Cancer 2001 94 2 252 256 11668506
42 Pollack SM Jungbluth AA Hoch BL NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma Cancer 2012 118 18 4564 4570 22359263
43 Wölfl M Jungbluth AA Garrido F Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma Cancer Immunol Immunother 2005 54 4 400 406 15449039
44 Rodolfo M Luksch R Stockert E Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen Cancer Res 2003 63 20 6948 6955 14583496
45 Barrow C Browning J MacGregor D Tumor antigen expression in melanoma varies according to antigen and stage Clin Cancer Res 2006 12 3 Pt 1 764 771 16467087
46 Dhodapkar MV Osman K Teruya-Feldstein J Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease Cancer Immun 2003 3 9 12875607
47 Suyama T Shiraishi T Zeng Y Expression of cancer/testis antigens in prostate cancer is associated with disease progression Prostate 2010 70 16 1778 1787 20583133
48 Chaux P Luiten R Demotte N Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1 J Immunol 1999 163 5 2928 2936 10453041
49 Chianese-Bullock KA Pressley J Garbee C MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma J Immunol 2005 174 5 3080 3086 15728523
50 Carrasco J Van Pel A Neyns B Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells J Immunol 2008 180 5 3585 3593 18292586
51 Thurner B Haendle I Röder C Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 1999 190 11 1669 1678 10587357
52 Connerotte T Van Pel A Godelaine D Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities Cancer Res 2008 68 10 3931 3940 18483279
53 Goodyear O Agathanggelou A Novitzky-Basso I Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia Blood 2010 116 11 1908 1918 20530795
54 Nishikawa H Maeda Y Ishida T Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma Blood 2012 119 13 3097 3104 22323448
55 Jäger E Nagata Y Gnjatic S Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses Proc Natl Acad Sci U S A 2000 97 9 4760 4765 10781081
56 Jäger E Gnjatic S Nagata Y Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers Proc Natl Acad Sci U S A 2000 97 22 12198 12203 11027314
57 MacKensen A Herbst B Chen JL Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells Int J Cancer 2000 86 3 385 392 10760827
58 Shackleton M Davis ID Hopkins W The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand Cancer Immun 2004 4 9 15384929
59 Chen Q Jackson H Shackleton M Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination Cancer Immun 2005 5 5 15755075
60 Bender A Karbach J Neumann A LUD 00-009: phase 1study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer Cancer Immun 2007 7 16 17944437
61 Davis ID Chen W Jackson H Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans Proc Natl Acad Sci U S A 2004 101 29 10697 10702 15252201
62 Nicholaou T Chen W Davis ID Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ Cancer Immunol Immunother 2011 60 11 1625 1637 21698545
63 Robert C Thomas L Bondarenko I Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 2011 364 26 2517 2526 21639810
64 Rosenblatt J Glotzbecker B Mills H PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine J Immunother 2011 34 5 409 418 21577144
65 Gulley JL Arlen PM Bastian A Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer Clin Cancer Res 2005 11 9 3353 3362 15867235
66 Arlen PM Gulley JL Parker C A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Clin Cancer Res 2006 12 4 1260 1269 16489082
67 Laheru D Lutz E Burke J Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res 2008 14 5 1455 1463 18316569
68 Farsaci B Higgins JP Hodge JW Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy Int J Cancer 2012 130 8 1948 1959 21633954
69 Stagg J Loi S Divisekera U Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy Proc Natl Acad Sci U S A 2011 108 17 7142 7147 21482773
70 Vanneman M Dranoff G Combining immunotherapy and targeted therapies in cancer treatment Nat Rev Cancer 2012 12 4 237 251 22437869
71 Rech AJ Vonderheide RH Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Ann N Y Acad Sci 2009 1174 99 106 19769742
72 Jacobs JF Punt CJ Lesterhuis WJ Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients Clin Cancer Res 2010 16 20 5067 5078 20736326
73 Zhao J Cao Y Lei Z Yang Z Zhang B Huang B Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels Cancer Res 2010 70 12 4850 4858 20501849
74 van der Most RG Currie AJ Mahendran S Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy Cancer Immunol Immunother 2009 58 8 1219 1228 19052741
75 De Smet C Lurquin C Lethé B DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter Mol Cell Biol 1999 19 11 7327 7335 10523621
76 Ye Q Shen Y Wang X Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer Tissue Antigens 2010 75 1 30 39 19883394
77 Marks P Rifkind RA Richon VM Breslow R Miller T Kelly WK Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 2001 1 3 194 202 11902574
78 Yang H Hoshino K Sanchez-Gonzalez B Kantarjian H Garcia-Manero G Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid Leuk Res 2005 29 7 739 748 15927669
79 Garcia-Manero G Gore SD Future directions for the use of hypomethylating agents Semin Hematol 2005 42 3 Suppl 2 S50 S59 16015506
80 Issa JP Gharibyan V Cortes J Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate J Clin Oncol 2005 23 17 3948 3956 15883410
81 Adair SJ Hogan KT Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules Cancer Immunol Immunother 2009 58 4 589 601 18791715
82 Schrump DS Fischette MR Nguyen DM Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura Clin Cancer Res 2006 12 19 5777 5785 17020984
83 Weber J Salgaller M Samid D Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine Cancer Res 1994 54 7 1766 1771 7511051
84 Almstedt M Blagitko-Dorfs N Duque-Afonso J The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells Leuk Res 2010 34 7 899 905 20381863
85 Serrano A Tanzarella S Lionello I Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment Int J Cancer 2001 94 2 243 251 11668505
86 Sigalotti L Altomonte M Colizzi F 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 2003 101 11 4644 4646 12756166
87 Oi S Natsume A Ito M Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells J Neurooncol 2009 92 1 15 22 19030781
88 Natsume A Wakabayashi T Tsujimura K The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma Int J Cancer 2008 122 11 2542 2553 18240144
89 Bao L Dunham K Lucas K MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing Cancer Immunol Immunother 2011 60 9 1299 1307 21626030
90 Krishnadas DK Shapiro T Lucas K Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma Pediatrics 2013 131 1 e336 e341 23266925
91 Robbins PF Morgan RA Feldman SA Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 2011 29 7 917 9290 21282551
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.